Indivior Makes a Strategic Shift to US GAAP Reporting
Indivior PLC (NASDAQ: INDV), a prominent global pharmaceutical company, has recently announced its transition to U.S. Generally Accepted Accounting Principles (GAAP). This significant shift is part of their broader strategy to move its primary stock listing to the United States, a decision aimed at increasing interest among U.S. analysts and investors.
Details of the Transition
Indivior secured approval from its shareholders to proceed with this transition, which aligns with the company’s ambitions for a more robust presence in the U.S. market. Starting from the fiscal year 2025, financial results will be reported under US GAAP. This is expected to make Indivior more attractive to U.S. investors and facilitate its inclusion in major U.S. equity indices.
Implications for Financial Reporting
The move to US GAAP involves the reconciliation of historical financial statements, previously prepared under the International Financial Reporting Standards (IFRS), to the new standard. This reconciled financial data will be accessible via Indivior's official website, providing greater transparency and consistency for stakeholders.
Future Financial Guidance
With this transition, Indivior plans to present future financial guidance according to US GAAP. The comparative figures for the year ending December 31, 2024, will be released concurrently with the FY 2024 IFRS results in February 2025. This dual presentation is designed to ease the adjustment period for their investors.
Commitment to Transparency
As part of its commitment to transparency, Indivior will file all future financial statements using the SEC Form 10-K and SEC Form 10-Q. By adopting these U.S. reporting standards, the company aims to enhance its credibility in the eyes of potential investors, ensuring that they receive detailed and standardized financial information.
Focus on Substance Use Disorder Treatments
Indivior is globally recognized for its dedication to treating substance use disorders (SUD). The company’s mission is to reshape SUD from what is currently perceived as a global crisis into a chronic disease that deserves understanding, recognition, and treatment. Headquartered in Richmond, VA, Indivior operates in over 30 countries, making a significant impact in the field of addiction treatment.
Global Operations and Market Impact
With its innovative treatment solutions, Indivior continues striving to meet the needs of patients worldwide. The transition to US GAAP reporting not only aligns with their strategic goals but also emphasizes their commitment to delivering value to their stakeholders.
Frequently Asked Questions
What is US GAAP reporting?
US GAAP refers to the Generally Accepted Accounting Principles used in the United States for financial reporting, ensuring consistency and transparency.
Why is Indivior transitioning to US GAAP?
The transition aims to attract U.S. investors and facilitate Indivior's listing in major U.S. equity indices, enhancing its market presence.
When will Indivior start reporting under US GAAP?
Indivior plans to adopt US GAAP reporting for the fiscal year 2025, with financial results prepared accordingly.
How will this transition affect investors?
This transition is expected to provide investors with improved financial reporting, fostering greater engagement and trust in the company's performance.
What is Indivior's specialization?
Indivior specializes in developing treatments for substance use disorders, aiming to transform this global issue into a recognized chronic disease.
